세계의 엑소좀 시장 : 시장 점유율과 순위, 전체 판매 및 수요 예측(2025-2031년)

The global market for Exosomes was estimated to be worth US$ 628 million in 2024 and is forecast to a readjusted size of US$ 1728 million by 2031 with a CAGR of 15.3% during the forecast period 2025-2031.

Exosomes are nanoscale extracellular vesicles with diameters of approximately 30-150 nanometers, secreted by various cell types through exocytosis under physiological or pathological conditions. Found in biological fluids such as blood, urine, and cerebrospinal fluid, they carry a wide range of biomolecules including proteins, lipids, DNA, mRNA, and miRNA, playing a key role in intercellular communication, immune regulation, tumor progression, tissue repair, and neurodegenerative disease pathways. Advances in nanoscale isolation technologies, biomarker identification, and high-throughput omics research have positioned exosomes as powerful tools for liquid biopsy and early disease diagnosis, as well as promising vectors for targeted drug delivery, immune modulation therapies, and regenerative medicine. Today, exosomes are transitioning from research applications to commercial clinical products and novel drug development, serving as a critical component of precision medicine, cell therapy, and RNA-based therapeutics, attracting significant attention from regulatory agencies and global investors.

The exosome industry is experiencing rapid expansion, driven by surging demand for precision medicine, breakthroughs in liquid biopsy and early diagnostic technologies, and the commercialization of RNA drug delivery platforms. According to reports from leading pharmaceutical and biotech companies, exosomes have been incorporated into oncology, immunology, and neurodegenerative disease pipelines, with several candidates advancing into clinical trials. Capital investment remains strong, and leading CDMO providers are accelerating the development of exosome manufacturing processes and GMP-compliant facilities. Government support for regenerative medicine and advanced therapies is further accelerating the transition of exosomes from research to commercial-scale production. With their natural delivery capabilities and low immunogenicity, exosomes are emerging as a key complement to cell and nucleic acid therapeutics, offering vast market potential.

Despite its high growth potential, the exosome sector faces substantial challenges, including high technical barriers, lack of standardized protocols, and an evolving commercial model. Current isolation and purification techniques remain costly and low-yield, hindering scalability. Global regulatory frameworks are fragmented, with significant variations in quality control, clinical certification, and safety evaluation requirements, slowing commercialization and global market expansion. Additionally, intense competition in intellectual property creates significant entry barriers, particularly for smaller firms. Investor caution over clinical progress and commercialization strategies also introduces uncertainty, emphasizing the need for continuous technological innovation and scalable manufacturing solutions.

Downstream applications are rapidly expanding from research-driven markets to commercial clinical services and therapeutic products. The growth of liquid biopsy is enhancing exosomes' role as a non-invasive diagnostic biomarker, while their use in drug delivery and immune modulation is improving the precision and safety of cell and gene therapies. The aesthetics and anti-aging markets are also creating new demand for exosome-based products. Advances in AI-driven omics, automated purification platforms, and scalable bioprocessing will enable high-throughput, high-sensitivity, and industrial-scale production. With the rapid growth of precision medicine and RNA therapeutics, exosomes are poised to become a major innovation driver in the biopharmaceutical industry over the next 5-10 years.

This report aims to provide a comprehensive presentation of the global market for Exosomes, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Exosomes by region & country, by Type, and by Application.

The Exosomes market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Exosomes.

Market Segmentation

By Company

• CellResearch
• ExoCoBio
• Skinlabs Medical
• Thermo Fisher Scientific
• Qiagen
• System Biosciences (SBI)
• Merck
• Norgen Biotek
• StemCells21
• Codiak Biosciences
• Exosome Diagnostics
• Evox Therapeutics
• Aegle Therapeutics
• Danaher
• Lonza

Segment by Type

• Scientific Research Products
• Beauty and Anti-aging
• Treatment and Diagnosis

Segment by Application

• Tumors
• Neurological Diseases
• Regenerative Medicine
• Other

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Exosomes company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Exosomes in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Exosomes in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Exosomes Product Introduction
• 1.2 Global Exosomes Market Size Forecast (2020-2031)
• 1.3 Exosomes Market Trends & Drivers
  • 1.3.1 Exosomes Industry Trends
  • 1.3.2 Exosomes Market Drivers & Opportunity
  • 1.3.3 Exosomes Market Challenges
  • 1.3.4 Exosomes Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Exosomes Players Revenue Ranking (2024)
• 2.2 Global Exosomes Revenue by Company (2020-2025)
• 2.3 Key Companies Exosomes Manufacturing Base Distribution and Headquarters
• 2.4 Key Companies Exosomes Product Offered
• 2.5 Key Companies Time to Begin Mass Production of Exosomes
• 2.6 Exosomes Market Competitive Analysis
  • 2.6.1 Exosomes Market Concentration Rate (2020-2025)
  • 2.6.2 Global 5 and 10 Largest Companies by Exosomes Revenue in 2024
  • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Exosomes as of 2024)
• 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Scientific Research Products
  • 3.1.2 Beauty and Anti-aging
  • 3.1.3 Treatment and Diagnosis
• 3.2 Global Exosomes Sales Value by Type
  • 3.2.1 Global Exosomes Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Exosomes Sales Value, by Type (2020-2031)
  • 3.2.3 Global Exosomes Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Tumors
  • 4.1.2 Neurological Diseases
  • 4.1.3 Regenerative Medicine
  • 4.1.4 Other
• 4.2 Global Exosomes Sales Value by Application
  • 4.2.1 Global Exosomes Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Exosomes Sales Value, by Application (2020-2031)
  • 4.2.3 Global Exosomes Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

• 5.1 Global Exosomes Sales Value by Region
  • 5.1.1 Global Exosomes Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Exosomes Sales Value by Region (2020-2025)
  • 5.1.3 Global Exosomes Sales Value by Region (2026-2031)
  • 5.1.4 Global Exosomes Sales Value by Region (%), (2020-2031)
• 5.2 North America
  • 5.2.1 North America Exosomes Sales Value, 2020-2031
  • 5.2.2 North America Exosomes Sales Value by Country (%), 2024 VS 2031
• 5.3 Europe
  • 5.3.1 Europe Exosomes Sales Value, 2020-2031
  • 5.3.2 Europe Exosomes Sales Value by Country (%), 2024 VS 2031
• 5.4 Asia Pacific
  • 5.4.1 Asia Pacific Exosomes Sales Value, 2020-2031
  • 5.4.2 Asia Pacific Exosomes Sales Value by Region (%), 2024 VS 2031
• 5.5 South America
  • 5.5.1 South America Exosomes Sales Value, 2020-2031
  • 5.5.2 South America Exosomes Sales Value by Country (%), 2024 VS 2031
• 5.6 Middle East & Africa
  • 5.6.1 Middle East & Africa Exosomes Sales Value, 2020-2031
  • 5.6.2 Middle East & Africa Exosomes Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Exosomes Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Exosomes Sales Value, 2020-2031
• 6.3 United States
  • 6.3.1 United States Exosomes Sales Value, 2020-2031
  • 6.3.2 United States Exosomes Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Exosomes Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Exosomes Sales Value, 2020-2031
  • 6.4.2 Europe Exosomes Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Exosomes Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Exosomes Sales Value, 2020-2031
  • 6.5.2 China Exosomes Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Exosomes Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Exosomes Sales Value, 2020-2031
  • 6.6.2 Japan Exosomes Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Exosomes Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Exosomes Sales Value, 2020-2031
  • 6.7.2 South Korea Exosomes Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Exosomes Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Exosomes Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Exosomes Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Exosomes Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Exosomes Sales Value, 2020-2031
  • 6.9.2 India Exosomes Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Exosomes Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 CellResearch
  • 7.1.1 CellResearch Profile
  • 7.1.2 CellResearch Main Business
  • 7.1.3 CellResearch Exosomes Products, Services and Solutions
  • 7.1.4 CellResearch Exosomes Revenue (US$ Million) & (2020-2025)
  • 7.1.5 CellResearch Recent Developments
• 7.2 ExoCoBio
  • 7.2.1 ExoCoBio Profile
  • 7.2.2 ExoCoBio Main Business
  • 7.2.3 ExoCoBio Exosomes Products, Services and Solutions
  • 7.2.4 ExoCoBio Exosomes Revenue (US$ Million) & (2020-2025)
  • 7.2.5 ExoCoBio Recent Developments
• 7.3 Skinlabs Medical
  • 7.3.1 Skinlabs Medical Profile
  • 7.3.2 Skinlabs Medical Main Business
  • 7.3.3 Skinlabs Medical Exosomes Products, Services and Solutions
  • 7.3.4 Skinlabs Medical Exosomes Revenue (US$ Million) & (2020-2025)
  • 7.3.5 Skinlabs Medical Recent Developments
• 7.4 Thermo Fisher Scientific
  • 7.4.1 Thermo Fisher Scientific Profile
  • 7.4.2 Thermo Fisher Scientific Main Business
  • 7.4.3 Thermo Fisher Scientific Exosomes Products, Services and Solutions
  • 7.4.4 Thermo Fisher Scientific Exosomes Revenue (US$ Million) & (2020-2025)
  • 7.4.5 Thermo Fisher Scientific Recent Developments
• 7.5 Qiagen
  • 7.5.1 Qiagen Profile
  • 7.5.2 Qiagen Main Business
  • 7.5.3 Qiagen Exosomes Products, Services and Solutions
  • 7.5.4 Qiagen Exosomes Revenue (US$ Million) & (2020-2025)
  • 7.5.5 Qiagen Recent Developments
• 7.6 System Biosciences (SBI)
  • 7.6.1 System Biosciences (SBI) Profile
  • 7.6.2 System Biosciences (SBI) Main Business
  • 7.6.3 System Biosciences (SBI) Exosomes Products, Services and Solutions
  • 7.6.4 System Biosciences (SBI) Exosomes Revenue (US$ Million) & (2020-2025)
  • 7.6.5 System Biosciences (SBI) Recent Developments
• 7.7 Merck
  • 7.7.1 Merck Profile
  • 7.7.2 Merck Main Business
  • 7.7.3 Merck Exosomes Products, Services and Solutions
  • 7.7.4 Merck Exosomes Revenue (US$ Million) & (2020-2025)
  • 7.7.5 Merck Recent Developments
• 7.8 Norgen Biotek
  • 7.8.1 Norgen Biotek Profile
  • 7.8.2 Norgen Biotek Main Business
  • 7.8.3 Norgen Biotek Exosomes Products, Services and Solutions
  • 7.8.4 Norgen Biotek Exosomes Revenue (US$ Million) & (2020-2025)
  • 7.8.5 Norgen Biotek Recent Developments
• 7.9 StemCells21
  • 7.9.1 StemCells21 Profile
  • 7.9.2 StemCells21 Main Business
  • 7.9.3 StemCells21 Exosomes Products, Services and Solutions
  • 7.9.4 StemCells21 Exosomes Revenue (US$ Million) & (2020-2025)
  • 7.9.5 StemCells21 Recent Developments
• 7.10 Codiak Biosciences
  • 7.10.1 Codiak Biosciences Profile
  • 7.10.2 Codiak Biosciences Main Business
  • 7.10.3 Codiak Biosciences Exosomes Products, Services and Solutions
  • 7.10.4 Codiak Biosciences Exosomes Revenue (US$ Million) & (2020-2025)
  • 7.10.5 Codiak Biosciences Recent Developments
• 7.11 Exosome Diagnostics
  • 7.11.1 Exosome Diagnostics Profile
  • 7.11.2 Exosome Diagnostics Main Business
  • 7.11.3 Exosome Diagnostics Exosomes Products, Services and Solutions
  • 7.11.4 Exosome Diagnostics Exosomes Revenue (US$ Million) & (2020-2025)
  • 7.11.5 Exosome Diagnostics Recent Developments
• 7.12 Evox Therapeutics
  • 7.12.1 Evox Therapeutics Profile
  • 7.12.2 Evox Therapeutics Main Business
  • 7.12.3 Evox Therapeutics Exosomes Products, Services and Solutions
  • 7.12.4 Evox Therapeutics Exosomes Revenue (US$ Million) & (2020-2025)
  • 7.12.5 Evox Therapeutics Recent Developments
• 7.13 Aegle Therapeutics
  • 7.13.1 Aegle Therapeutics Profile
  • 7.13.2 Aegle Therapeutics Main Business
  • 7.13.3 Aegle Therapeutics Exosomes Products, Services and Solutions
  • 7.13.4 Aegle Therapeutics Exosomes Revenue (US$ Million) & (2020-2025)
  • 7.13.5 Aegle Therapeutics Recent Developments
• 7.14 Danaher
  • 7.14.1 Danaher Profile
  • 7.14.2 Danaher Main Business
  • 7.14.3 Danaher Exosomes Products, Services and Solutions
  • 7.14.4 Danaher Exosomes Revenue (US$ Million) & (2020-2025)
  • 7.14.5 Danaher Recent Developments
• 7.15 Lonza
  • 7.15.1 Lonza Profile
  • 7.15.2 Lonza Main Business
  • 7.15.3 Lonza Exosomes Products, Services and Solutions
  • 7.15.4 Lonza Exosomes Revenue (US$ Million) & (2020-2025)
  • 7.15.5 Lonza Recent Developments

8 Industry Chain Analysis

• 8.1 Exosomes Industrial Chain
• 8.2 Exosomes Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Exosomes Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Exosomes Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer